Clinical trials: Moderate Plaque Psoriasis
Plaque-type Psoriasis
AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis
The purpose of this study was to provide long term clinical data for the compound for the treatment of the indication of moderate to severe chronic plaque-type psoriasis.
- Trial name
- NCT01132612
- Testing
- AIN457
- Where
- 57 sites in United States, France and 5 more
- Volunteers
- 275 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Evaluation of the Efficacy and Tolerability of Clobetasol Propionate Foam Compared to Vehicle Foam
The purpose of the study is to compare the efficacy and safety of Clobetasol propionate to that of its Vehicle in the treatment of mild to moderate plaque-type psoriasis.
- Trial name
- NCT00842153
- Testing
- Clobetasol propionate foam, Vehicle foam
- Where
- 2 sites in United States
- Volunteers
- 58 people
- Sponsor
- Stiefel, a GSK Company
Psoriasis
Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis
The purpose of the study is to evaluate the efficacy, safety, pharmacokinetics, immunogenicity, usability, and acceptability of guselkumab delivered using SelfDose device in participants with moderate to severe plaque-type…
- Trial name
- NCT02905331
- Testing
- Guselkumab
- Where
- 14 sites in United States, Canada and 1 more
- Volunteers
- 78 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis
A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis
This was a Phase 2, international, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, 12-week study. It was designed to assess the therapeutic dose, efficacy, and safety of treatment with SAR441566 in male…
- Trial name
- SPECIFI-PSO (NCT06073119)
- Testing
- SAR441566
- Where
- 51 sites in United States, Argentina and 15 more
- Volunteers
- 221 people
- Sponsor
- Sanofi
Psoriasis Vulgaris
Long Term Safety and Efficacy Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
The objective of this study is to evaluate the safety and efficacy of up to 26 weeks of treatment with calcitriol 3 mcg/g ointment when used twice daily, without occlusion, to treat pediatric subjects (2 to 16 years and 11 months…
- Trial name
- NCT02125279
- Testing
- Calcitriol
- Where
- 16 sites in United States, Belgium and 3 more
- Volunteers
- 54 people
- Sponsor
- Galderma R&D
Chronic Plaque Psoriasis
Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/Photochemotherapy
A study to assess the safety and efficacy of 2 different doses of CDP870 versus placebo, administered during 12 weeks, to patients suffering from moderate to severe chronic plaque psoriasis, extended by a 12 to 24 week follow-up.
- Trial name
- NCT00245765
- Testing
- Certolizumab Pegol
- Where
- 15 sites in France, Germany
- Volunteers
- 176 people
- Sponsor
- UCB Pharma
Palmo-plantar Psoriasis
Apremilast in Palmo-Plantar Psoriasis
This study will compare the safety and efficacy of Apremilast 30mg to placebo in subjects with moderate to severe plaque psoriasis involving palms and/or soles.
- Trial name
- NCT02400749
- Testing
- Apremilast
- Where
- 11 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- Innovaderm Research Inc.
Chronic Stable Plaque Psoriasis
A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis
This study will compare the efficacy and safety of DFD-06 Cream to Vehicle Cream for topical treatment of moderate to severe plaque psoriasis after 3, 7, and 14 days of treatment.
- Trial name
- NCT02445807
- Testing
- DFD06-Cream, Vehicle Cream
- Where
- 30 sites in United States
- Volunteers
- 265 people
- Sponsor
- Promius Pharma, LLC
Psoriasis
Safety, Tolerability And Efficacy Study Of Topical PF-06763809 In Subjects With Mild To Moderate Chronic Plaque Psoriasis
The study is a randomized, double blinded, vehicle and active comparator controlled, multiple dose study in subjects with chronic plaque psoriasis. The study will have approximately 15 completers.
- Trial name
- NCT03469336
- Testing
- PF-06763809, Vehicle, Calcipotriene/calcipotriol
- Where
- 2 sites in Germany
- Volunteers
- 18 people
- Sponsor
- Pfizer
Plaque Psoriasis
A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis.
Study of effects of secukinumab 300 mg s.c. on quality of life (QoL) in psoriasis in patients with or without prior exposure to systemic therapy.
- Trial name
- PROSE (NCT02752776)
- Testing
- Secukinumab
- Where
- 215 sites in Belgium, Bulgaria and 15 more
- Volunteers
- 1,660 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Plaque Psoriasis
TRUST Study: Raptiva ® in Hand & Foot Psoriasis
To evaluate the safety and efficacy of Raptiva ® compared with placebo to control chronic moderate to severe plaque psoriasis involving the hands and/or feet scoring Physician's Global Assessment (PGA - H\&F) greater-than or…
- Trial name
- TRUST (NCT00739882)
- Testing
- Efalizumab - anti CD11a recombinant human monoclonal antibody
- Where
- Austria
- Volunteers
- 76 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Chronic Stable Plaque Psoriasis
Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Etanercept (GP2015) and Enbrel
The purpose of this study is to demonstrate equivalent efficacy of GP2015 and Enbrel® in patients with moderate to severe chronic plaque-type psoriasis with respect to PASI 75 response rate at Week 12.
- Trial name
- EGALITY (NCT01891864)
- Testing
- GP2015 Etanercept, Enbrel
- Where
- 74 sites in Bulgaria, Czechia and 10 more
- Volunteers
- 531 people
- Sponsor
- Sandoz
Plaque Psoriasis
The Effect of Enstilar Versus Vehicle on Target Lesions in Moderate Plaque Type Psoriasis Patients
This study seeks to show whether there is a benefit of prescribing Enstilar in the treatment of patients with moderate plaque type psoriasis. Subjects will receive study treatment of Enstilar foam.
- Trial name
- NCT03848871
- Testing
- Enstilar
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Derm Research, PLLC
Psoriasis
Desoximetasone Spray 0.25%, Hypothalamic Pituitary Adrenal (HPA) Axis Study
The objective of this study is to evaluate the potential of desoximetasone 0.25% topical spray to suppress HPA axis function. The potential for adrenal suppression will be assessed following multiple dosing with Desoximetasone…
- Trial name
- NCT01043393
- Testing
- Desoximetasone 0.25% spray
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Psoriasis
Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab.
Severe psoriasis has been demonstrated to be associated with decreased endothelial function and an increase risk of future coronary events.
- Trial name
- NCT01320293
- Testing
- Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA]
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of North Carolina, Chapel Hill
Plaque Psoriasis
A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis
The main purpose of this study is to evaluate the efficacy of ixekizumab dosing regimens in participants with plaque psoriasis.
- Trial name
- IXORA-P (NCT02513550)
- Testing
- Ixekizumab
- Where
- 125 sites in United States, Argentina and 12 more
- Volunteers
- 1,257 people
- Sponsor
- Eli Lilly and Company
Scalp Psoriasis
Clobetasol Propionate Spray Versus Vehicle Spray for the Management of Moderate to Severe Plaque Psoriasis of the Scalp
The primary objective of this study is to evaluate the safety and efficacy of clobetasol propionate spray versus vehicle spray for the management of moderate to severe plaque psoriasis of the scalp.
- Trial name
- NCT00881868
- Testing
- clobetasol propionate spray 0.05%, Vehicle spray
- Where
- 4 sites in United States
- Volunteers
- 81 people
- Sponsor
- Galderma R&D
Plaque Psoriasis
Evaluate Safety/Efficacy of Two Treatment Regimens for Vectical™ Ointment & Clobex® Spray for Moderate Plaque Psoriasis
This clinical trial will evaluate the efficacy and safety of Clobex® (clobetasol propionate) Spray 0.05% and Vectical™ (calcitriol) Ointment 3 µg/g over a four week period of use in one of two different regimens: 1.
- Trial name
- NCT00988637
- Testing
- Vectical™ Ointment weekdays and Clobex® Spray weekends regimen, Clobex® Spray morning and Vectical™ Ointment evening regimen
- Where
- 6 sites in United States, Canada
- Volunteers
- 138 people
- Sponsor
- Galderma R&D
Psoriasis, Plaque Psoriasis
Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients
This Phase IIa study is designed to assess the safety, tolerability and pharmacokinetics of oral MP1032 in patients with moderate to severe psoriasis over a period of 6 weeks.
- Trial name
- NCT02908347
- Testing
- MP1032
- Where
- 4 sites in Germany
- Volunteers
- 46 people
- Sponsor
- MetrioPharm AG
Plaque Psoriasis
Efficacy/Safety/Subject Satisfaction/Duration of Response of Clobetasol Propionate Spray vs Ointment in Plaque Psoriasis
This study is a comparison between Clobetasol Propionate Spray and Clobetasol Propionate Ointment with Regard to Efficacy, Safety, Subject Satisfaction and Duration of Response in Moderate to Severe Stable Plaque Psoriasis.
- Trial name
- NCT00733954
- Testing
- clobetasol propionate spray, clobetasol propionate ointment
- Where
- 6 sites in United States
- Volunteers
- 250 people
- Sponsor
- Galderma R&D